Limits...
Foxp3+ Treg expanded from patients with established diabetes reduce Helios expression while retaining normal function compared to healthy individuals.

Du W, Shen YW, Lee WH, Wang D, Paz S, Kandeel F, Liu CP - PLoS ONE (2013)

Bottom Line: After isolation, Treg from both T1D patients and healthy subjects were successfully expanded with high purity.Importantly, expanded Treg from both subject groups were able to suppress autologous or allogeneic CD8(+) effector T cells equally well.Thus, based on the positive outcomes, these potent expanded Treg from diabetic human patients may be useful in treating T1D or preventing islet graft rejection.

View Article: PubMed Central - PubMed

Affiliation: Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California, United States of America.

ABSTRACT
Foxp3(+) regulatory T cells (Treg) play a crucial role in regulating immune tolerance. The use of Treg to restore immune tolerance is considered an attractive novel approach to inhibit autoimmune disease, including type 1 diabetes (T1D), and to prevent rejection of organ transplants. In view of the goal of developing autologous Treg-based cell therapy for patients with long-term (>15 years) T1D, it will be necessary to expand a sufficient amount of functional Treg in vitro in order to study and compare Treg from T1D patients and healthy subjects. Our results have demonstrated that there is a comparable frequency of Treg in the peripheral blood lymphocytes (PBLs) of patients with long-term T1D relative to those in healthy subjects; however, Th1 cells, but not Th17 cells, were increased in the T1D patients. Further, more Treg in PBLs from T1D patients than from healthy subjects expressed the CD45RO(+) memory cell phenotype, suggesting they were antigen-experienced cells. After isolation, Treg from both T1D patients and healthy subjects were successfully expanded with high purity. Although there was no difference in Helios expression on Treg in PBLs, in vitro expansion led to fewer Helios-expressing Treg from T1D patients than healthy subjects. While more Th1-like Treg expressing IFN-γ or TNF-α were found in the PBLs of T1D patients than healthy controls, there was no such difference in the expanded Treg. Importantly, expanded Treg from both subject groups were able to suppress autologous or allogeneic CD8(+) effector T cells equally well. Our findings demonstrate that a large number of ex vivo expanded functional Treg can be obtained from long-term T1D patients, although fewer expanded Treg expressed a high level of Helios. Thus, based on the positive outcomes, these potent expanded Treg from diabetic human patients may be useful in treating T1D or preventing islet graft rejection.

Show MeSH

Related in: MedlinePlus

Comparable frequency of CD4+, CD8+ or Treg in PBLs of T1D patients and healthy subjects.PBMCs isolated from the whole blood of both diabetic patients and healthy controls were stained with indicated antibodies and analyzed by flow cytometry. (A) Percentage of CD4+ and CD8+ T cells in PBLs. (B) Ratios of CD4+ and CD8+ T cells (left) and the frequency of CD4+Foxp3+ Treg (right). The horizontal lines represent the median of all analyzed samples in each group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3569420&req=5

pone-0056209-g001: Comparable frequency of CD4+, CD8+ or Treg in PBLs of T1D patients and healthy subjects.PBMCs isolated from the whole blood of both diabetic patients and healthy controls were stained with indicated antibodies and analyzed by flow cytometry. (A) Percentage of CD4+ and CD8+ T cells in PBLs. (B) Ratios of CD4+ and CD8+ T cells (left) and the frequency of CD4+Foxp3+ Treg (right). The horizontal lines represent the median of all analyzed samples in each group.

Mentions: We first analyzed the percentage of CD4+ and CD8+ T cells in PBLs from both patients with established T1D and healthy subjects. As shown in Table 1, Fig. 1A–B, both groups had comparable percentages and ratio of CD4+ and CD8+ T cells. In addition, consistent with previous findings [24], there was no difference in the frequency of CD4+Foxp3+ Treg in the PBLs between T1D and healthy subjects (Fig. 1B).


Foxp3+ Treg expanded from patients with established diabetes reduce Helios expression while retaining normal function compared to healthy individuals.

Du W, Shen YW, Lee WH, Wang D, Paz S, Kandeel F, Liu CP - PLoS ONE (2013)

Comparable frequency of CD4+, CD8+ or Treg in PBLs of T1D patients and healthy subjects.PBMCs isolated from the whole blood of both diabetic patients and healthy controls were stained with indicated antibodies and analyzed by flow cytometry. (A) Percentage of CD4+ and CD8+ T cells in PBLs. (B) Ratios of CD4+ and CD8+ T cells (left) and the frequency of CD4+Foxp3+ Treg (right). The horizontal lines represent the median of all analyzed samples in each group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3569420&req=5

pone-0056209-g001: Comparable frequency of CD4+, CD8+ or Treg in PBLs of T1D patients and healthy subjects.PBMCs isolated from the whole blood of both diabetic patients and healthy controls were stained with indicated antibodies and analyzed by flow cytometry. (A) Percentage of CD4+ and CD8+ T cells in PBLs. (B) Ratios of CD4+ and CD8+ T cells (left) and the frequency of CD4+Foxp3+ Treg (right). The horizontal lines represent the median of all analyzed samples in each group.
Mentions: We first analyzed the percentage of CD4+ and CD8+ T cells in PBLs from both patients with established T1D and healthy subjects. As shown in Table 1, Fig. 1A–B, both groups had comparable percentages and ratio of CD4+ and CD8+ T cells. In addition, consistent with previous findings [24], there was no difference in the frequency of CD4+Foxp3+ Treg in the PBLs between T1D and healthy subjects (Fig. 1B).

Bottom Line: After isolation, Treg from both T1D patients and healthy subjects were successfully expanded with high purity.Importantly, expanded Treg from both subject groups were able to suppress autologous or allogeneic CD8(+) effector T cells equally well.Thus, based on the positive outcomes, these potent expanded Treg from diabetic human patients may be useful in treating T1D or preventing islet graft rejection.

View Article: PubMed Central - PubMed

Affiliation: Department of Diabetes and Metabolic Diseases Research, Beckman Research Institute, City of Hope, Duarte, California, United States of America.

ABSTRACT
Foxp3(+) regulatory T cells (Treg) play a crucial role in regulating immune tolerance. The use of Treg to restore immune tolerance is considered an attractive novel approach to inhibit autoimmune disease, including type 1 diabetes (T1D), and to prevent rejection of organ transplants. In view of the goal of developing autologous Treg-based cell therapy for patients with long-term (>15 years) T1D, it will be necessary to expand a sufficient amount of functional Treg in vitro in order to study and compare Treg from T1D patients and healthy subjects. Our results have demonstrated that there is a comparable frequency of Treg in the peripheral blood lymphocytes (PBLs) of patients with long-term T1D relative to those in healthy subjects; however, Th1 cells, but not Th17 cells, were increased in the T1D patients. Further, more Treg in PBLs from T1D patients than from healthy subjects expressed the CD45RO(+) memory cell phenotype, suggesting they were antigen-experienced cells. After isolation, Treg from both T1D patients and healthy subjects were successfully expanded with high purity. Although there was no difference in Helios expression on Treg in PBLs, in vitro expansion led to fewer Helios-expressing Treg from T1D patients than healthy subjects. While more Th1-like Treg expressing IFN-γ or TNF-α were found in the PBLs of T1D patients than healthy controls, there was no such difference in the expanded Treg. Importantly, expanded Treg from both subject groups were able to suppress autologous or allogeneic CD8(+) effector T cells equally well. Our findings demonstrate that a large number of ex vivo expanded functional Treg can be obtained from long-term T1D patients, although fewer expanded Treg expressed a high level of Helios. Thus, based on the positive outcomes, these potent expanded Treg from diabetic human patients may be useful in treating T1D or preventing islet graft rejection.

Show MeSH
Related in: MedlinePlus